false 0001855644 0001855644 2024-05-29 2024-05-29 0001855644 us-gaap:CommonClassAMember 2024-05-29 2024-05-29 0001855644 us-gaap:WarrantMember 2024-05-29 2024-05-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

May 29, 2024

Date of Report (Date of earliest event reported)

 

 

Zura Bio Limited

(Exact Name of Registrant as Specified in its Charter)

 

 

Cayman Islands   001-40598   98-1725736
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S Employer
Identification No.)

 

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

(Address of principal executive offices, including zip code)

 

(702) 757-6133

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading 
Symbol(s)		   Name of each exchange
on which registered
Class A Ordinary Shares, par value $0.0001 per share   ZURA   The Nasdaq Stock Market
Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share   ZURAW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR - 230.405) or Rule 12b - 2 of the Securities Exchange Act of 1934 (17 CFR - 240.12b - 2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On May 29, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Press Release dated May 29, 2024.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 29, 2024

 

  ZURA BIO LIMITED
   
  By: /s/ Kim Davis
    Kim Davis
    Chief Legal Officer

 

 

 

Exhibit 99.1

 

  

Zura Bio Announces Participation in June Investor Conferences

 

Henderson, Nev – May 29, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.

 

Conference Details: 

 

Event: Jefferies Global Healthcare Conference

Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.

 

Event: Oppenheimer Novel Targets in Immunology Summit

Details: Robert Lisicki, Chief Executive Officer, will participate in a “Novel Immunological Mechanisms for Dermatological Disorders” panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY.

 

ABOUT ZURA BIO

 

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

 

Contact

 

Megan K. Weinshank

Head of Investor Relations

ir@zurabio.com

 

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com

 

 

v3.24.1.1.u2
Cover
May 29, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 29, 2024
Entity File Number 001-40598
Entity Registrant Name Zura Bio Limited
Entity Central Index Key 0001855644
Entity Tax Identification Number 98-1725736
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 1489 W. Warm Springs Rd
Entity Address, Address Line Two #110
Entity Address, City or Town Henderson,
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89014
City Area Code 702
Local Phone Number 757-6133
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol ZURA
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
Trading Symbol ZURAW
Security Exchange Name NASDAQ
Zura Bio (NASDAQ:ZURAW)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Zura Bio Charts.
Zura Bio (NASDAQ:ZURAW)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Zura Bio Charts.